427 related articles for article (PubMed ID: 17056533)
21. Treatment with soluble interleukin-15Ralpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response.
Khan IA; Moretto M; Wei XQ; Williams M; Schwartzman JD; Liew FY
J Exp Med; 2002 Jun; 195(11):1463-70. PubMed ID: 12045244
[TBL] [Abstract][Full Text] [Related]
22. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
Guo Y; Luan L; Rabacal W; Bohannon JK; Fensterheim BA; Hernandez A; Sherwood ER
J Immunol; 2015 Sep; 195(5):2353-64. PubMed ID: 26216888
[TBL] [Abstract][Full Text] [Related]
23. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
24. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.
Wu Z; Xue HH; Bernard J; Zeng R; Issakov D; Bollenbacher-Reilley J; Belyakov IM; Oh S; Berzofsky JA; Leonard WJ
Blood; 2008 Dec; 112(12):4411-9. PubMed ID: 18796634
[TBL] [Abstract][Full Text] [Related]
25. Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
Thi VAD; Jeon HM; Park SM; Lee H; Kim YS
Mol Cells; 2019 Dec; 42(12):869-883. PubMed ID: 31760731
[TBL] [Abstract][Full Text] [Related]
26. IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells.
Kokaji AI; Hockley DL; Kane KP
J Immunol; 2008 Apr; 180(7):4391-401. PubMed ID: 18354159
[TBL] [Abstract][Full Text] [Related]
27. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells.
Sato N; Patel HJ; Waldmann TA; Tagaya Y
Proc Natl Acad Sci U S A; 2007 Jan; 104(2):588-93. PubMed ID: 17202253
[TBL] [Abstract][Full Text] [Related]
28. Homeostatic proliferation but not the generation of virus specific memory CD8 T cells is impaired in the absence of IL-15 or IL-15Ralpha.
Wherry EJ; Becker TC; Boone D; Kaja MK; Ma A; Ahmed R
Adv Exp Med Biol; 2002; 512():165-75. PubMed ID: 12405201
[TBL] [Abstract][Full Text] [Related]
29. The potential and promise of IL-15 in immuno-oncogenic therapies.
Robinson TO; Schluns KS
Immunol Lett; 2017 Oct; 190():159-168. PubMed ID: 28823521
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
[TBL] [Abstract][Full Text] [Related]
31. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation.
Mortier E; Woo T; Advincula R; Gozalo S; Ma A
J Exp Med; 2008 May; 205(5):1213-25. PubMed ID: 18458113
[TBL] [Abstract][Full Text] [Related]
32. Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.
Chertova E; Bergamaschi C; Chertov O; Sowder R; Bear J; Roser JD; Beach RK; Lifson JD; Felber BK; Pavlakis GN
J Biol Chem; 2013 Jun; 288(25):18093-103. PubMed ID: 23649624
[TBL] [Abstract][Full Text] [Related]
33. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
Ochoa MC; Fioravanti J; Rodriguez I; Hervas-Stubbs S; Azpilikueta A; Mazzolini G; Gúrpide A; Prieto J; Pardo J; Berraondo P; Melero I
Cancer Res; 2013 Jan; 73(1):139-49. PubMed ID: 23149919
[TBL] [Abstract][Full Text] [Related]
34. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
35. IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.
Tamzalit F; Barbieux I; Plet A; Heim J; Nedellec S; Morisseau S; Jacques Y; Mortier E
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8565-70. PubMed ID: 24912180
[TBL] [Abstract][Full Text] [Related]
36. Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.
Finch DK; Midha A; Buchanan CL; Cochrane D; Craggs RI; Cruwys S; Grahames C; Kolbeck R; Lowe DC; Maltby J; Pattison DV; Vousden KA; Ward A; Sleeman MA; Mallinder PR
Br J Pharmacol; 2011 Jan; 162(2):480-90. PubMed ID: 20942844
[TBL] [Abstract][Full Text] [Related]
37. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation.
Ota N; Takase M; Uchiyama H; Olsen SK; Kanagawa O
J Immunol; 2010 Nov; 185(10):6041-8. PubMed ID: 20926799
[TBL] [Abstract][Full Text] [Related]
38. Crosstalk between IL-15Rα
Zhang W; Zhang Q; Yang N; Shi Q; Su H; Lin T; He Z; Wang W; Guo H; Shen P
Cancer Commun (Lond); 2022 Jun; 42(6):536-557. PubMed ID: 35615815
[TBL] [Abstract][Full Text] [Related]
39. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
Steel JC; Ramlogan CA; Yu P; Sakai Y; Forni G; Waldmann TA; Morris JC
Cancer Res; 2010 Feb; 70(3):1072-81. PubMed ID: 20086176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
